(Press-News.org) A new randomised controlled trial has found promising evidence that the smoking cessation medication varenicline (Chantix/Champix) can help people with cannabis use disorder (CUD) to reduce cannabis use. CUD is a rising problem globally, partly due to recent legalization in several countries and US states, and until now no medications have been found to treat it.
CUD is characterized by continued use of cannabis despite ‘clinically significant impairment’ such as ignoring important social, occupational, or recreational activities and persistent use despite physical or psychological problems associated with cannabis. Cannabis use is also associated with psychosis, sleep disorders, withdrawal, and mood and anxiety disorders.
Varenicline is an effective medication for quitting tobacco. This trial, conducted at the Medical University of South Carolina and published in Addiction, tested whether varenicline could help with CUD. Results showed it helped men reduce cannabis use, but not women. (Varenicline works equally well for both sexes as a stop-smoking aid.)
The trial included 174 participants with CUD who used cannabis at least three days per week. Participants were randomized to varenicline (working up to a dose of 1 mg twice daily) or placebo for 12 weeks. Participants also received a weekly brief medical management session to encourage their adherence to both the medication and the treatment plan.
The men in the study who received varenicline used cannabis fewer times per week than the men on placebo. Specifically, the varenicline group averaged 7.9 cannabis sessions per week during the study and 5.7 sessions in the week following the study, compared with more than 12 weekly sessions for the placebo group. The male varenicline group also used cannabis an average of 3.8 days per week, compared with 4.7 days per week for the male placebo group.
The women in the study who received varenicline did not differ in their cannabis use from the women on placebo. The varenicline group averaged just over 10 sessions per week, compared with the placebo group’s 9.2 weekly sessions (which dropped to 8.2 in the week following the study). The female varenicline group used cannabis an average of 4.9 days per week, compared with 3.6 days for the female placebo group.
The female varenicline group showed higher withdrawal and craving scores and higher anxiety than any of the other groups. Perhaps connected with that, women receiving varenicline reported lower medication adherence than women receiving placebo.
Lead author Professor Aimee McRae-Clark says “Cannabis use disorder is rising quickly in the United States. Current pharmacological treatment options are very limited, and so our ability to help people reduce their cannabis use is also limited. Our study found that varenicline, a drug that helps people to reduce or stop smoking, may be effective at reducing cannabis use as well, but only for men. Our next step is to further explore varenicline for cannabis use disorder, using a larger sample size of women, to better understand this sex difference in the treatment outcome. In the meantime, we are encouraged that varenicline shows potential promise in treating this fast-growing problem.”
-- Ends –
For editors:
This Open Access paper is available on the Wiley Online Library from the embargo date (https://onlinelibrary.wiley.com/doi/10.1111/add.70296) or you may request an early copy from Jean O’Reilly, Editorial Manager, Addiction, jean@addictionjournal.org.
To speak with lead author Professor Aimee McRae-Clark, please contact her at the Medical University of South Carolina by email (mcraeal@musc.edu) or telephone (+1 843-792-5216).
Full citation for article: McRae-Clark AL, Gray KM, Baker NL, Sherman BJ, Tolliver B, Burt J, Steplight A, Chapman E, and Wagner A. Varenicline for cannabis use disorder: A randomized controlled trial. Addiction. 2026. DOI: 10.1111/add.70296
Primary funding: This work was supported by the National Institutes of Health (UH3DA043231).
Declaration of interests: Dr. McRae-Clark has served as a consultant for Indivior Pharmaceuticals and has received research support from Pleo Pharma. Dr. Gray has served as a consultant for Indivior Pharmaceuticals and received research support from Aelis Pharma. The other authors report no interests to be disclosed.
Addiction is a monthly international scientific journal publishing peer-reviewed research reports on alcohol, substances, tobacco, gambling, editorials, and other debate pieces. Owned by the Society for the Study of Addiction, it has been in continuous publication since 1884.
END
Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results.
The sepsis drug candidate, a carbohydrate-based drug called STC3141, was co-developed by Distinguished Professor Mark von Itzstein AO and his team from Griffith’s Institute for Biomedicine and Glycomics, and Professor Christopher Parish and his team at The Australian National University.
“The trial met the key endpoints to indicate the drug candidate was successful in reducing sepsis in humans,” Professor von Itzstein said.
STC3141 was administered as an infusion via a cannula and counteracted ...
Playing video games for more than 10 hours a week could have a significant impact on young people’s diet, sleep and body weight, according to a new Curtin University-led study published in Nutrition.
Researchers surveyed 317 students from five Australian universities with a median age of 20 years old.
They split participants into three groups depending on the self-reported amount of time spent playing video games, from ‘low gamers’ (0-5 hours per week) to ‘moderate gamers’ (5-10 hours) and ‘high gamers’ ...
Background
Various tissues and organs in the human body, such as nerves, heart, bones, and skin, rely on bioelectrical signals to maintain function and support regeneration. Although conventional electrical therapies are effective, they require external power sources and invasive electrodes, leading to high risks of infection and reduced patient comfort. This review innovatively proposes the use of electrospinning to fabricate electroactive fibrous scaffolds, which mimic the structure of the extracellular matrix while providing electrical activity, thereby enabling non-invasive and self-powered tissue repair.
Research Progress
Electrically sensitive ...
Fingertip monitors known as pulse oximeters that can be used at home to detect low blood oxygen levels (hypoxaemia) give higher readings for patients with darker than lighter skin tones, finds the largest study on this topic published by The BMJ today.
This means that low blood oxygen levels may be missed in patients with darker skin tones, potentially delaying care, while patients with lighter skin tones may get unnecessary treatment.
Pulse oximeters use light to measure the amount of oxygen in the blood (SpO2). For most people, a normal pulse oximeter reading is between 95% and 100%, with readings below 90-92% generally considered low and requiring medical ...
Wearing a cast for six weeks appears to be no less effective than surgery for healing unstable ankle fractures and carries fewer treatment related harms, finds a clinical trial from Finland published by The BMJ today.
Around two thirds of all ankle fractures involve a break in the fibula (the outer ankle bone). Known as Weber B fractures, they leave the ankle either stable or unstable (at risk of falling out of alignment).
Surgery remains the main treatment for Weber B ankle fractures deemed unstable, despite recent trials and guidelines increasingly supporting non-surgical options in selected patients.
To explore this further, researchers set out ...
Alcohol-free and low alcohol (“nolo”) drinks have the potential to improve public health, but experts in The BMJ today call for a precautionary approach that maximises potential benefits (eg. increased substitution of alcoholic drinks with nolo alternatives) while minimising risks (eg. preventing encroachment of nolo drinks into alcohol-free spaces).
Sales of alcohol-free and low alcohol drinks have increased substantially over recent years, driven by improved manufacturing techniques and consumer demand for better and healthier alternatives to alcoholic drinks, ...
Key findings
Adding 100 mL of water at room temperature (25 ℃) to 1 g of the alloy powder results in nearly complete hydrolysis and yields a high hydrogen output in a short time. After correcting for water vapor, the measured hydrogen volume corresponds to approximately 737–760 mL H₂ per gram of powder (produced within about 10 minutes).
Raising the water temperature to 60 ℃ further increases both reaction rate and total yield, reaching up to ≈835 mL H₂/g (uncorrected value).
Microstructural analysis using SEM/TEM/EDS shows that the gas-atomized powders are spherical (diameter ~6–65 ...
Archival discoveries including a 19th-century autobiography transform our understanding of Shadrack Byfield, an English veteran of the War of 1812 who buried his own amputated arm and designed a custom prosthesis. A recurrent character in TV documentaries, books and museum exhibits in the USA and Canada, Byfield has been celebrated as an uncomplaining British soldier. But the new evidence reveals Byfield’s tenacious pursuit of veterans’ benefits and his struggles with pain, poverty, and the police.
‘They came and pushed me about, ...
The University of Birmingham today (15 Jan) launched a new West Midlands-based facility for separating and recycling rare earth magnets that will help to reduce the UK’s reliance on imports of rare earth metals, alloys, and magnets.
Rare earth magnets are amongst the key ‘critical minerals’ that are integral to modern life. They form a core building block in technologies such as wind turbines, electric vehicles, medical equipment, pumps, robotics, and electronics. Demand for these minerals will only increase as the adoption of low-carbon technologies ...
The Oceanography Society (TOS) has selected Dr. Corday Selden, an Assistant Professor at Rutgers University, as a recipient of the TOS Early Career Award, recognizing her outstanding early-career research contributions, leadership in ocean sciences, and exceptional promise for future impact in oceanography. Dr. Selden will be recognized at The Oceanography Society Honors Breakfast, February 24, 2026, during the Ocean Sciences Meeting in Glasgow, Scotland.
Dr. Selden is a marine biogeochemist whose research has fundamentally advanced understanding of how marine microbial processes regulate ocean chemistry and Earth-system function. Her work integrates stable isotope geochemistry, ...
